Induction of anti-tumor immunity by dendritic cells pulsed with an endoplasmic reticulum retrieval signal modifies heparanase epitope in mice

References

• Rolle CE, Carrio R, Malek TR. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. Cancer Res. 2008;68:2984–92.
   PubMed Web of Science ®Google Scholar
• Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, . Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res. 2005;65:6435–42.
   Google Scholar
• Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, . High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425–33.
   PubMed Web of Science ®Google Scholar
• Alves PM, Viatte S, Fagerberg T, Michielin O, Bricard G, Bouzourene H, . Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother. 2007;56:1795–805.
   PubMed Web of Science ®Google Scholar
• Gross G, Margalit A. Targeting tumor-associated antigens to the MHC class I presentation pathway. Endocr Metab Immune Disord Drug Targets. 2007;7:99–109.
   PubMedGoogle Scholar
• Cohen S, Haimovich J, Hollander N. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol. 2009;182:1667–73.
   PubMed Web of Science ®Google Scholar
• Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, . Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 2006;13:630–40.
   PubMed Web of Science ®Google Scholar
• Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, . Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer. 2005;116:934–43.
   PubMed Web of Science ®Google Scholar
• Kumagi T, Akbar SM, Horiike N, Onji M. Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells. Int J Oncol. 2003;23:949–55.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, . Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539–48.
   PubMed Web of Science ®Google Scholar
• Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, . Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750–8.
   PubMed Web of Science ®Google Scholar
• Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, . An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol. 1998;72:1469–81.
   PubMed Web of Science ®Google Scholar
• Sherritt M, Cooper L, Moss DJ, Kienzle N, Altman J, Khanna R. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with downregulated expression of MHC and peptide transporters. Int Immunol. 2001;13:265–71.
   PubMed Web of Science ®Google Scholar
• Minev BR, Chavez FL, Dudouet BM, Mitchell MS. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1. Eur J Immunol. 2000;30:2115–24.
   PubMed Web of Science ®Google Scholar
• Pichon C, Arar K, Stewart AJ, Dodon MD, Gazzolo L, Courtoy PJ, . Intracellular routing and inhibitory activity of oligonucleopeptides containing a KDEL motif. Mol Pharmacol. 1997;51:431–8.
   PubMed Web of Science ®Google Scholar
• Pap EH, Dansen TB, van Summeren R, Wirtz KW. Peptide-based targeting of fluorophores to organelles in living cells. Exp Cell Res. 2001;265:288–93.
   PubMed Web of Science ®Google Scholar
• Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99–108.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001;108:341–7.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Goldshmidt O, Zcharia E, Metzger S, Chajek-Shaul T, Atzmon R, . Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie. 2001;83:831–9.
   PubMed Web of Science ®Google Scholar
• Tang XD, Wan Y, Chen L, Chen T, Yu ST, Xiong Z, . H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo. Cancer Res. 2008;68:1529–37.
   PubMed Web of Science ®Google Scholar
• Lu L, Hsieh M, Oriss TB, Morel PA, Starzl TE, Rao AS, . Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology. 1995;84:127–34.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert review of anticancer therapy. 2007;7:1225–41.
   PubMed Web of Science ®Google Scholar
• Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol Oncol. 2006;24:47–55.
   PubMed Web of Science ®Google Scholar
• Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280–5.
   PubMed Web of Science ®Google Scholar
• Sbiera S, Wortmann S, Fassnacht M. Dendritic cell based immunotherapy: a promising therapeutic approach for endocrine malignancies. Horm Metab Res. 2008;40:89–98.
   PubMed Web of Science ®Google Scholar
• Aragoneses-Fenoll L, Corbi AL. Dendritic cells: still a promising tool for cancer immunotherapy. Clin Transl Oncol. 2007;9:77–82.
   PubMed Web of Science ®Google Scholar
• Maisnier-Patin K, Crabe S, Breton G, Dupuy FP, Yassine-Diab B, Sekaly RP. [mRNA-transfected dendritic cells: a promising strategy in immunotherapy]. Med Sci (Paris). 2007;23:279–84.
   PubMed Web of Science ®Google Scholar
• Dauer M, Schnurr M, Eigler A. Dendritic cell-based cancer vaccination: quo vadis? Expert Rev Vaccines. 2008;7:1041–53.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007;7:790–802.
   PubMed Web of Science ®Google Scholar
• Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, . Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis. Clin Cancer Res. 2008;14:6055–61.
   PubMed Web of Science ®Google Scholar
• Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, . Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res. 2005;65:5778–84.
   PubMed Web of Science ®Google Scholar
• McKenzie EA. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol. 2007;151:1–14.
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Chen Y, Zhao HJ, Xie CY, Ding J, Hou YT. Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo. Cancer Biol Ther. 2007;6:587–95.
   PubMed Web of Science ®Google Scholar
• Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG, Marchetti D. Antisense-mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia (New York). 2005;7:253–62.
   PubMed Web of Science ®Google Scholar
• Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Ins. 2004;96:1219–30.
   PubMed Web of Science ®Google Scholar
• Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, Yanagishita M, . Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res. 2001;92:1062–73.
   PubMedGoogle Scholar
• Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, . Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest. 2003; 83:613–22.
   PubMed Web of Science ®Google Scholar
• Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines. Curr Opin Immunol. 2000;12:583–8.
   PubMed Web of Science ®Google Scholar
• Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv Cancer Res. 2008;99: 363–407.
   PubMedGoogle Scholar
• Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q, . A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol. 2007;179:6009–15.
   PubMed Web of Science ®Google Scholar
• Bullock TN, Colella TA, Engelhard VH. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol. 2000;164:2354–61.
   PubMed Web of Science ®Google Scholar
• Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev. 1999; 169:45–54.
   PubMed Web of Science ®Google Scholar
• Franz A, Maass K, Seedorf M. A complex peptide-sorting signal, but no mRNA signal, is required for the Sec- independent transport of Ist2 from the yeast ER to the plasma membrane. FEBS Lett. 2007;581:401–5.
   PubMed Web of Science ®Google Scholar
• Brandizzi F, Hanton S, DaSilva LL, Boevink P, Evans D, Oparka K, . ER quality control can lead to retrograde transport from the ER lumen to the cytosol and the nucleoplasm in plants. Plant J. 2003;34:269–81.
   PubMed Web of Science ®Google Scholar